Orient Europharma’s subsidiary, Orient Pharma, recently submitted an application to the Taipei Exchange for over-the-counter (OTC) listing. If the review process proceeds smoothly, the company is expected to debut in the second half of the year. The integration of internal business and marketing resources within the OEP Group has shown clear results, driving product sales and customer expansion. As a result, Orient Pharma achieved a 37% year-on-year growth in revenue in 2024, with operating profit soaring by 549% and net income after tax increasing by 381%, leading to earnings per share (EPS) of NT$0.48.
In May 2022, the OEP Group implemented a strategy of professional specialization and resource integration, transferring the business operations of Orient Europharma’s Prescription Medicine Business Division II to Orient Pharma. As part of the restructuring, Orient Pharma issued new shares to Orient Europharma as payment for the asset transfer, thereby increasing Orient Europharma’s stake in Orient Pharma from 51.82% to 59.60%.
Orient Pharma focuses on the development, manufacturing, and sales of new pharmaceutical products. Its core portfolio includes medications for the central nervous system, lipid-lowering agents, antibiotics, and diabetes treatments. The company also engages in contract development and manufacturing services (CDMO) for other pharmaceutical firms. Its marketed products include niche generics and two 505(b)(2) new drug applications: Methydur, a treatment for attention deficit hyperactivity disorder (ADHD); Vancomycin, an anti-infective generic; and Pitavastatin, a lipid-lowering agent. The company is actively expanding into Asian markets and has initiated regulatory submissions in countries including China and across Southeast Asia.
In 2024, Orient Pharma reported consolidated revenue of NT$1.222 billion, representing a 37% year-on-year increase. Operating profit surged by 549%, and net income after tax rose to NT$107 million, marking a 381% jump. EPS reached NT$0.48, up significantly from NT$0.10 the previous year. The company attributes this robust improvement in performance to the successful integration of internal business and marketing resources during 2023. This synergy has begun to bear fruit, and ongoing efforts in 2024 to drive product sales and customer development have contributed to the company’s continued revenue and profit growth.
Resource: 友霖送件申請上櫃，集團資源整合成效顯，去年EPS大增四倍達0.48元
